SCHEMBL7873282

SCHEMBL7873282

COC(=O)c1cc2ccccc2n1OC

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 1/20 0.56
MTNR1B P49286 1/20 0.56
KMT2A Q03164 1/20 0.48
MCL1 Q07820 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 2/20 0.45
KDM4E B2RXH2 2/20 0.45
DAO P14920 1/20 0.45
MAPT P10636 1/20 0.45
NOD2 Q9HC29 1/20 0.44
NOD1 Q9Y239 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TSHR P16473 1/20 0.42
CRHBP P24387 1/20 0.42
CRHR2 Q13324 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4102690 0.85 PLA2G10 (0.49) MTNR1AMTNR1BMCL1ALDH1A1DAO
SCHEMBL4445494 0.85 MCL1 (0.62) MTNR1AMTNR1BKMT2AMCL1ALDH1A1
SCHEMBL2458550 0.84 NOD2 (0.62) MTNR1AMTNR1BKMT2AMCL1ALDH1A1
SCHEMBL9987683 0.84 MCL1 (0.45) MTNR1AMTNR1BKMT2AMCL1ALDH1A1
SCHEMBL30234519 0.84 MCL1 (0.45) MTNR1AMTNR1BKMT2AMCL1ALDH1A1
SCHEMBL6988070 0.82 MTNR1A (0.51) MTNR1AMTNR1BKMT2AMCL1L3MBTL1
SCHEMBL4740170 0.81 MTNR1A (0.53) MTNR1AMTNR1BKMT2AMCL1L3MBTL1
SCHEMBL29834903 0.81 L3MBTL1 (0.67) MTNR1AMTNR1BKMT2AMCL1L3MBTL1
SCHEMBL7884242 0.81 DAO (0.64) MTNR1AMTNR1BKMT2AMCL1L3MBTL1
SCHEMBL4486403 0.81 L3MBTL1 (0.67) MTNR1AMTNR1BKMT2AMCL1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed